Xcovery is an evidence-based, innovation-driven biopharmaceutical company with a mission to improve the lives of individuals battling advanced stages of cancer worldwide. Through advanced science, Xcovery creates cutting-edge oncology therapies that not only surpass the effectiveness of current options but are also less toxic and more tolerable for patients in need. One of their leading products, Ensartinib, stands as a potentially best-in-class ALK inhibitor.

It targets abnormal forms of ALK, which are key drivers of certain non-small cell lung cancer and neuroblastomas. Ensartinib showcases promising clinical antitumor activity, offering hope to patients affected by these cancers. In addition, Xcovery has developed Vorolanib, a next-generation orally active multikinase inhibitor.

This innovative therapy has shown efficacy against various cancers by inhibiting angiogenesis, the process that fuels tumor growth. Through monotherapy and combination therapy, Vorolanib has demonstrated its potential to make a significant difference in the lives of cancer patients. Xcovery seeks partnerships to launch Ensartinib globally and in the United States, as well as to develop Vorolanib as an ideal combination partner for immuno-oncology therapy.

They are also open to investors who recognize the immense value of targeted therapeutics in the field of oncology. With a passion for science and a commitment to improving cancer treatment, Xcovery is dedicated to bringing hope and progress to those affected by this devastating disease